Pfizer Canada and BioNTech Receive Health Canada Approval of Omicron KP.2 Variant Adapted COVID-19 Vaccine
Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 variant adapted COMIRNATY® COVID-19 vaccine for ages 6 months and older. The updated COMIRNATY® vaccine targets the Omicron KP.
Zacks.com on MSN1d
PFE & BNTX Get Positive CHMP Opinion for Updated COVID-19 JabPFE along with BioNTech SE BNTX announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
These five top stocks trade at reasonable levels and offer the strength that makes sense as we enter a very volatile time of ...
SEPANG: Dr Roland Victor, who is charged with making and initiating the transmission of offensive videos about the Covid-19 ...
The latest strain of the COVID-19 virus, XEC, is circulating across the country. The new variant has been reported in at ...
The University of Pennsylvania has sued German biotechnology firm BioNTech in Pennsylvania federal court, accusing the ...
With a volume of 492,652, the price of BNTX is up 6.46% at $111.78. RSI indicators hint that the underlying stock may be ...
Hosted on MSN5d
Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?Pfizer PFE stock has risen 7.3% in the past three months compared with an increase of 2.9% for the industry. The stock has ...
With the approval of Moderna's updated COVID-19 vaccine, doctors are hoping the shots will be available soon and Albertans ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback